vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Mayville Engineering Company, Inc. (MEC). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $134.3M, roughly 1.8× Mayville Engineering Company, Inc.). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs -3.2%, a 14.4% gap on every dollar of revenue. On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 10.7%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $10.2M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs -8.8%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Mayville Engineering Company, Inc. is a U.S.-headquartered leading manufacturer of metal components, fabricated assemblies, and custom engineered solutions. It serves OEM clients across agriculture, construction, transportation, defense, and power sports markets, offering end-to-end services from prototyping to high-volume production for North America.
ANIP vs MEC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $134.3M |
| Net Profit | $27.5M | $-4.4M |
| Gross Margin | — | 6.8% |
| Operating Margin | 14.1% | -4.1% |
| Net Margin | 11.1% | -3.2% |
| Revenue YoY | 29.6% | 10.7% |
| Net Profit YoY | 367.5% | -127.3% |
| EPS (diluted) | $1.14 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $134.3M | ||
| Q3 25 | $227.8M | $144.3M | ||
| Q2 25 | $211.4M | $132.3M | ||
| Q1 25 | $197.1M | $135.6M | ||
| Q4 24 | $190.6M | $121.3M | ||
| Q3 24 | $148.3M | $135.4M | ||
| Q2 24 | $138.0M | $163.6M | ||
| Q1 24 | $137.4M | $161.3M |
| Q4 25 | $27.5M | $-4.4M | ||
| Q3 25 | $26.6M | $-2.7M | ||
| Q2 25 | $8.5M | $-1.1M | ||
| Q1 25 | $15.7M | $20.0K | ||
| Q4 24 | $-10.3M | $16.0M | ||
| Q3 24 | $-24.2M | $3.0M | ||
| Q2 24 | $-2.3M | $3.8M | ||
| Q1 24 | $18.2M | $3.2M |
| Q4 25 | — | 6.8% | ||
| Q3 25 | — | 11.0% | ||
| Q2 25 | — | 10.3% | ||
| Q1 25 | — | 11.3% | ||
| Q4 24 | — | 8.9% | ||
| Q3 24 | — | 12.6% | ||
| Q2 24 | — | 13.6% | ||
| Q1 24 | — | 13.0% |
| Q4 25 | 14.1% | -4.1% | ||
| Q3 25 | 15.9% | 0.0% | ||
| Q2 25 | 6.6% | 0.1% | ||
| Q1 25 | 13.3% | 1.2% | ||
| Q4 24 | -2.3% | 19.0% | ||
| Q3 24 | -13.8% | 4.2% | ||
| Q2 24 | 3.7% | 5.0% | ||
| Q1 24 | 14.8% | 4.7% |
| Q4 25 | 11.1% | -3.2% | ||
| Q3 25 | 11.7% | -1.9% | ||
| Q2 25 | 4.0% | -0.8% | ||
| Q1 25 | 8.0% | 0.0% | ||
| Q4 24 | -5.4% | 13.2% | ||
| Q3 24 | -16.3% | 2.2% | ||
| Q2 24 | -1.7% | 2.3% | ||
| Q1 24 | 13.2% | 2.0% |
| Q4 25 | $1.14 | $-0.22 | ||
| Q3 25 | $1.13 | $-0.13 | ||
| Q2 25 | $0.36 | $-0.05 | ||
| Q1 25 | $0.69 | $0.00 | ||
| Q4 24 | $-0.45 | $0.76 | ||
| Q3 24 | $-1.27 | $0.14 | ||
| Q2 24 | $-0.14 | $0.18 | ||
| Q1 24 | $0.82 | $0.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $1.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $240.7M |
| Total Assets | $1.4B | $563.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $1.5M | ||
| Q3 25 | $262.6M | $1.2M | ||
| Q2 25 | $217.8M | $206.0K | ||
| Q1 25 | $149.8M | $183.0K | ||
| Q4 24 | $144.9M | $206.0K | ||
| Q3 24 | $145.0M | $178.0K | ||
| Q2 24 | $240.1M | $314.0K | ||
| Q1 24 | $228.6M | $314.0K |
| Q4 25 | $540.7M | $240.7M | ||
| Q3 25 | $505.8M | $244.8M | ||
| Q2 25 | $436.8M | $246.8M | ||
| Q1 25 | $418.6M | $250.0M | ||
| Q4 24 | $403.7M | $251.8M | ||
| Q3 24 | $405.9M | $238.4M | ||
| Q2 24 | $455.8M | $238.1M | ||
| Q1 24 | $452.0M | $234.0M |
| Q4 25 | $1.4B | $563.6M | ||
| Q3 25 | $1.4B | $585.6M | ||
| Q2 25 | $1.3B | $433.7M | ||
| Q1 25 | $1.3B | $447.7M | ||
| Q4 24 | $1.3B | $445.6M | ||
| Q3 24 | $1.3B | $466.0M | ||
| Q2 24 | $920.8M | $488.2M | ||
| Q1 24 | $914.5M | $499.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $13.4M |
| Free Cash FlowOCF − Capex | $29.1M | $10.2M |
| FCF MarginFCF / Revenue | 11.8% | 7.6% |
| Capex IntensityCapex / Revenue | 0.5% | 2.4% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $26.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $13.4M | ||
| Q3 25 | $44.1M | $1.9M | ||
| Q2 25 | $75.8M | $15.0M | ||
| Q1 25 | $35.0M | $8.3M | ||
| Q4 24 | $15.9M | $38.0M | ||
| Q3 24 | $12.5M | $17.9M | ||
| Q2 24 | $17.4M | $23.3M | ||
| Q1 24 | $18.3M | $10.6M |
| Q4 25 | $29.1M | $10.2M | ||
| Q3 25 | $38.0M | $-1.1M | ||
| Q2 25 | $71.8M | $12.5M | ||
| Q1 25 | $32.5M | $5.4M | ||
| Q4 24 | $13.5M | $35.6M | ||
| Q3 24 | $7.7M | $15.1M | ||
| Q2 24 | $13.0M | $19.2M | ||
| Q1 24 | $13.7M | $7.8M |
| Q4 25 | 11.8% | 7.6% | ||
| Q3 25 | 16.7% | -0.8% | ||
| Q2 25 | 34.0% | 9.5% | ||
| Q1 25 | 16.5% | 4.0% | ||
| Q4 24 | 7.1% | 29.4% | ||
| Q3 24 | 5.2% | 11.1% | ||
| Q2 24 | 9.4% | 11.7% | ||
| Q1 24 | 10.0% | 4.9% |
| Q4 25 | 0.5% | 2.4% | ||
| Q3 25 | 2.7% | 2.1% | ||
| Q2 25 | 1.9% | 1.8% | ||
| Q1 25 | 1.3% | 2.2% | ||
| Q4 24 | 1.3% | 1.9% | ||
| Q3 24 | 3.2% | 2.1% | ||
| Q2 24 | 3.2% | 2.5% | ||
| Q1 24 | 3.3% | 1.7% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | — | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 416.65× | ||
| Q4 24 | — | 2.38× | ||
| Q3 24 | — | 6.03× | ||
| Q2 24 | — | 6.15× | ||
| Q1 24 | 1.00× | 3.28× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
MEC
| Fabrication | $72.2M | 54% |
| Construction And Access | $19.2M | 14% |
| Tubes | $16.2M | 12% |
| Other Market | $11.9M | 9% |
| Agriculture | $7.7M | 6% |
| Military | $6.7M | 5% |
| Outdoor Sports | $1.7M | 1% |
